Abstract:Due to the association of hormone replacement therapy (HRT) with breast cancer risk, estrogenically active soy isoflavones are considered as an HRT alternative to alleviate menopausal symptoms. However, several recent reports challenged the health benefits of soy isoflavones and associated them with breast cancer promotion. While glyconic isoflavones are the major constituents of soybean seeds, due to their low cell permeability, they are considered to be biologically inactive. The glyconic isoflavones may exert their effects on membrane-bound estrogen receptors or could be converted to aglycones by extracellular β-glucosidases. Therefore, we hypothesized that despite their low cell permeability, soybean cultivars with high glyconic isoflavones may promote breast cancer cell growth. To test this, composition and estrogenic activity of isoflavones from 54 commercial soybean cultivars were determined. Soybean seeds produced in identical climate and growth conditions were used to minimize the effects of extraneous factors on isoflavone profile and concentrations. The glyconic daidzin concentration negatively correlated with genistin and with other aglycones. Relative to control, isoflavone extracts from 51 cultivars were estrogenic and promoted the growth of estrogen receptor positive (ER+) breast cancer cell line MCF-7 from 1.14 to 4.59 folds and other three cultivars slightly reduced the growth. Among these, extracts from three cultivars were highly estrogenic and promoted MCF-7 cell growth by 2.59-4.64 folds (P<0.005). Among six isoflavones, daidzin was positively associated with MCF-7 cell growth (P<0.005, r = 0.13966), whereas the negative correlation between genistin and MCF-7 cell growth was nearly significant (P≤0.0562, r = -0.026141). Furthermore, in drug interaction studies daidzin-rich isoflavone extracts antagonized tamoxifen, an ER inhibitor. Taken together, our results suggest that the glyconic daidzin-rich soy isoflavone extracts may exert estrogenic effects and promote ER+ breast cancer growth.

Inhibition of environmental estrogen-induced proliferation of human breast carcinoma MCF-7 cells by flavonoids

Prenylflavonoids as nonsteroidal phytoestrogens and related structure-activity relationships.

Estrogen-like Effects of Ethanol Extracts from Several Chinese Legumes on MCF-7 Cell

Estrogenic effects of two derivatives of icariin on human breast cancer MCF-7 cells

Proliferation-stimulating effects of icaritin and desmethylicaritin in MCF-7 cells.

On Single and Combined Estrogenic Effects of Bisphenol A and 17Β-Estradiol at Low Dose Assessed Using MCF-7 Cell Proliferation

Effect of 3,6-Dihydroxyflavone on proliferation of MCF-7 cell lines

Inhibitory actions of genistein in human breast cancer (MCF-7) cells

Flavonoid Effects Relevant to Cancer

Effect of genistein on growth of human breast cancer cell MCF-7

Effects of Bisphenol A and Diazinon on Proliferation of MCF·7 Cells

[Assessment of the Estrogenicity of Endosulfan and Other Chemicals with the in Vitro Proliferation of Human Breast Cancer Cell]

Effects of genistein and daidzein on the cell growth, cell cycle, and differentiation of human and murine melanoma cells11The abbreviations used are: BSA, bovine serum albumin; FBS, fetal bovine serum; ECM, extracellular matrix; DMSO, dimethyl sulfoxide; PTK, protein tyrosine kinase.

EFFECTS OF SECOISOLARICIRESINOL ON PROLIFERATION OF BREAST CANCER MCF-7 CELLS

Glycone-rich Soy Isoflavone Extracts Promote Estrogen Receptor Positive Breast Cancer Cell Growth

The Combination of 17-Estradiol and Bisphenol A Weaken their Respective Action

[Genistein Exerts Multiple Suppressive Effects on Human Breast Carcinoma Cells].

Treatment with Phytoestrogens Reversed Triclosan and Bisphenol A-Induced Anti-Apoptosis in Breast Cancer Cells

The Biphasic Effect of Flavonoids on Oxidative Stress and Cell Proliferation in Breast Cancer Cells

Synthesis of Four Natural Prenylflavonoids and Their Estrogen-Like Activities

Effect of Estrogen on Heteronemin-Induced Anti-proliferative Effect in Breast Cancer Cells With Different Estrogen Receptor Status